GSA Capital Partners LLP Boosts Holdings in Evolent Health, Inc $EVH

GSA Capital Partners LLP boosted its position in Evolent Health, Inc (NYSE:EVH) by 1,715.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 308,149 shares of the technology company’s stock after buying an additional 291,173 shares during the period. GSA Capital Partners LLP’s holdings in Evolent Health were worth $1,233,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EVH. Brighton Jones LLC acquired a new stake in Evolent Health in the fourth quarter valued at $3,927,000. Eventide Asset Management LLC lifted its holdings in Evolent Health by 54.0% in the third quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company’s stock valued at $53,246,000 after acquiring an additional 2,205,659 shares during the period. Tudor Investment Corp ET AL lifted its holdings in Evolent Health by 174.4% in the third quarter. Tudor Investment Corp ET AL now owns 689,262 shares of the technology company’s stock valued at $5,831,000 after acquiring an additional 438,095 shares during the period. Rock Point Advisors LLC lifted its holdings in Evolent Health by 21.6% in the fourth quarter. Rock Point Advisors LLC now owns 1,190,156 shares of the technology company’s stock valued at $4,761,000 after acquiring an additional 211,707 shares during the period. Finally, Tejara Capital Ltd acquired a new stake in Evolent Health in the fourth quarter valued at $5,326,000.

Wall Street Analysts Forecast Growth

EVH has been the subject of a number of recent analyst reports. Wall Street Zen raised Evolent Health from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. BMO Capital Markets reissued an “outperform” rating and issued a $3.50 target price on shares of Evolent Health in a report on Wednesday, February 25th. KeyCorp downgraded Evolent Health from an “overweight” rating to a “sector weight” rating in a report on Wednesday, February 25th. Royal Bank Of Canada reduced their target price on Evolent Health from $5.00 to $3.00 and set a “sector perform” rating for the company in a report on Wednesday, February 25th. Finally, Needham & Company LLC raised their target price on Evolent Health from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Evolent Health presently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Evolent Health Trading Down 0.6%

NYSE:EVH opened at $3.87 on Thursday. The company has a market capitalization of $434.74 million, a PE ratio of -0.81 and a beta of 0.83. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 2.46. Evolent Health, Inc has a 52-week low of $2.10 and a 52-week high of $12.06. The stock has a fifty day simple moving average of $3.06 and a 200-day simple moving average of $3.57.

Evolent Health (NYSE:EVH) last released its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.03. The business had revenue of $496.25 million during the quarter, compared to the consensus estimate of $534.00 million. Evolent Health had a positive return on equity of 0.36% and a negative net margin of 26.29%.The business’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.06 EPS. On average, equities research analysts expect that Evolent Health, Inc will post -0.23 earnings per share for the current fiscal year.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.